Skip to main content
. Author manuscript; available in PMC: 2014 Jan 14.
Published in final edited form as: Clin Immunol. 2010 May 15;136(3):329–337. doi: 10.1016/j.clim.2010.04.014

Figure 4.

Figure 4

Ex vivo expanded CD4+Foxp3+ Treg cells from patients with immune-mediated diseases acquired enhanced inhibitory activities. In vitro suppressive function of expanded human Treg cells at week 2 and freshly purified Treg cells from some of the patients were measured with a standardized T cell proliferation inhibition assay. Expanded or freshly purified human Treg cells were serially diluted and added into the cultures at different Treg/T effector ratios as indicated. The percentage of inhibition of T effector cell proliferation by either expanded or fresh Treg cells was shown in Fig. 4. Each line represents a single patient.